And Second-Line Pharmacological Evaluations (IQIRVO / Elafibranor): Ongoing. While the core Phase III ELATIVE trial established the drug's safety profile, tracking its real-world impact is very much active. Major updates and new long-term extensions monitoring real-world fatigue and quality-of-life improvements continue to be heavily presented at global medical congresses like EASL

Yes on Friday, October 30, 2026, Stockholm-based biotech company Umecrine Cognition released topline results from the second part of its Phase 1b/2a clinical trial (UCAB-CT-05) evaluating its drug candidate, golexanolone, for primary biliary cholangitis (PBC) related fatigue and cognitive symptoms.

Key Outcomes of the Trial

• Efficacy Miss: Golexanolone did not demonstrate a statistically significant improvement over the placebo in its primary, prespecified cognitive endpoint (measured via the PBC-40 cognition score). Additionally, it showed no treatment benefit in the supportive analysis tracking PBC-related fatigue.
• Safety Profile: The drug was well-tolerated. Severe adverse events were infrequent and evenly balanced between the placebo and treatment groups, with mild gastrointestinal issues being the most common side effect.
• Data Value: Despite the negative trial results, the study successfully generated valuable metrics validating patient-reported and clinician-rated assessment scales for measuring the highly subjective burdens of central fatigue and brain fog in future trials.

I found out about this from
A PBC Foundation Q and A session as the expert presenting mentioned they were about to travel to Stockholm and look at the results data and they said to look out for the press release on Fri 30 Oct.

Dr Mark Swain in Canada and Professor David Jones in UK are two key people involved in this area of ongoing research looking at fatigue.

There is also "RELIEF: Multimodal Prehabilitation to Treat Fatigue in Patients With Primary Biliary Cholangitis" (ClinicalTrials.gov ID: NCT07161245).
The study is designed to directly address the persistent, debilitating fatigue and "brain fog" that affects up to 60% of people living with PBC. It evaluates how a structured, non-drug approach—combining personalized physical exercise, nutritional guidance, and psychological support—impacts fatigue severity and the underlying muscle and brain changes.